Dr. Holodick performed her undergraduate work at Northeastern University in Boston, Ma. She obtained her PhD in Immunology from Boston University in 2009, working on signaling and development of B-1 cells. Dr. Holodick expanded her work on B-1 cells during a postdoctoral fellowship at the Feinstein Institute for Medical Research in Manhasset, NY. During this time, she focused her research on the role of B-1 cells in infection during aging.
Recently, Dr. Holodick was appointed to Assistant Professor in the Center for Immunobiology and Department of Biomedical Sciences at WMed. In addition, Dr. Holodick is currently serving as Scientific Director for the Flow Cytometry Core facility.
B-1 cells are essential for immediate protection and therefore survival against bacterial and vial infections. Murine B-1a cells are defined by unique surface marker expression (CD45loCD5+IgMhighIgDlowCD43+CD19highMAC1+) as well distinct functional characteristics. B-1a cells arise mainly during fetal development, and their persistence throughout adult life is maintained through self-renewal.
Our work is focused on how B-1 cells change with age in relation to their ability to protect against infection. We study these changes with age in relation to B-1 cell development and mechanism of antibody secretion. Streptococcus pneumoniae is the most common cause of pneumonia, which claims the lives of people over the age of 65 seven times more frequently than those aged 5-49. B-1a cells provide immediate and essential protection from S. pneumoniae through production of natural antibody. Our research is aimed at understanding the mechanism of natural Ig change with age but also during disease.
Sickle cell disease (SCD) is one of the most common blood disorders affecting millions of people worldwide. One of the major causes of death for those with SCD is infection, in particular Streptococcus pneumoniae infection. Despite current interventions such as prophylactic antibiotics and vaccination, pneumococcal infection still poses a great risk to sickle cell patients. Our current studies are aimed at understanding whether B-1a cells and the protective antibodies they produce are altered in sickle cell disease.
Our laboratory group is committed to pursuing inquiry, disseminating knowledge, and fostering critical thinking that encourages lifelong learning. Take a look at a comprehensive listing of Dr. Holodick's most recent publications.